cancer in 5, pancreatic cancer in 2, and gastric cancer in 1) treated with GKS at the University of Virginia between January 1996 and December 2006. Patients were treated either by Dr. Ladislau Steiner or Dr. Jason Sheehan.
The patient population included 18 women and 22 men, with ages ranging from 33 to 86 years (mean age 58.7 years) ( Table 1) . The frequency with which the pa tients underwent GKS was as follows: 1 time in 28 pa tients; 2 times in 9 patients; 3 times in 1 patient; and 4 times in 2 patients.
Preoperative symptoms included headaches (14 pa tients), motor weakness (9) , gait imbalances (6), seizure (1) , and speech disturbance (1) . Six patients were neuro logically asymptomatic.
The mean KPS score was 70 (range . Accord ing to the Radiation Therapy Oncology Group's RPA clas sification system, 25 33 (82.5%) patients were RPA class II, 2 (5%) were RPA class III, and 5 (12.5%) were RPA class I. The SIR, which is based on the classification system of Weltman et al., 48 was used to stratify 30 patients (75%) as ≤ 6 and 10 patients (25%) as ≥ 7.
Thirteen patients (32.5%) had only brain metastases in addition to their primary cancer, whereas 24 patients (60%) had extracranial metastases that included the lung in 14 patients (35%), liver in 10 patients (25%), ovary in 1 patient (2.5%), omentum in 1 patient (2.5%), and the lymph nodules in 6 patients (15%). Three patients had a second primary cancer (breast, ovary, or lung cancer). Twenty patients (50%) had a single metastasis, and 20 (50%) had multiple metastases (mean 2.95; range 1-16 tumors).
Treatments prior to GKS included the following: WBRT only (11 patients, 27.5%), local brain radiotherapy only (3, 7 .5%), IMRT only (1, 2.5%), WBRT and local brain radiotherapy (4, 10%), resection (10, 25%), and adju vant systemic chemotherapy (27, 67 .5%). The 15 patients who underwent WBRT received a mean dose of 33.7 Gy (range 30-40 Gy).
A total of 118 tumors in 40 patients were treated with GKS. Tumor locations included the following: frontal lobe (31 tumors), temporal lobe (17), parietal lobe (11), occipi tal lobe (20) , cerebellum (29) , brainstem (5), basal ganglia or thalamus (2), corpus callosum (1), cerebellopontine angle (1), and intraventricular (1). Repeated radiosurgery was offered for those with new brain metastases.
Radiosurgical Technique
All patients underwent SRS performed using the Leksell Gamma Knife (Elekta Instruments). After place ment of the Leksell Model G stereotactic frame (Elekta Instruments), all patients underwent stereotactic MR im aging. The MR imaging was performed using contrast enhanced, T1weighted sequences. Both coronal and axial scans were acquired during each imaging session.
A computerized planning system (GammaPlan, Elek ta AB,) was used to construct a conformal irradiated volume to the tumor volume through the placement of 1 or more isocenters. Dose selection and planning were performed by a neurosurgeon, a radiation oncologist, and a medical physicist.
The dose delivered to the tumor margin ranged from 6 to 24 Gy (mean 18.4 Gy). The maximum tumor dose varied from 17.1 to 76.7 Gy (mean 41.8 Gy) ( ).
Follow-Up Data
After SRS, clinical followup data were obtained from the patients and the referring physician. Followup MR imaging studies were also performed at 3, 6, and 12 months for the 1st year, and thereafter at 3 to 6month intervals.
We categorized the followup imaging results into groups as follows: complete regression, defined by no visible tumor on follow-up MR imaging; partial regres sion, defined by a decrease in tumor volume of > 15%; no change, defined by stable volumetry ± 15%; and progres sion, defined by a volume increase of > 15%, based on the tumor volumetric analysis performed using the computa tional geometry technique. 45 
Statistical Analysis
The KaplanMeier method was used to calculate the survival time of patients. The logrank test was used to compare 2 groups in univariate analyses of categorical variables. The Cox proportional hazard model was used in analyses of categorical variables and continuous vari ables. In all cases, a probability value of < 0.05 was de fined as statistically significant after analysis using SPSS version 14.0 (SPSS, Inc.) and Microsoft Office Excel 2003 (Microsoft Corp.).
Results

Follow-Up MR Imaging and Local Tumor Control
In this series, complete followup MR images were available in 25 patients (90 tumors). Complete regression was observed in 2 patients (8%), partial regression in 4 (16%), no change in 12 (48%), and progression in 7 (28%). Local tumor control (that is, no growth or tumor shrink age) was achieved in 82 (91%) of 90 tumors evaluated, whereas progressive metastatic lesions were seen in 8 tumors (9%). Progressive disease was observed in 7 pa tients after GKS for a median of 6 months (range 1.1-14.2 months). These patients underwent systemic treatment without tumor removal, GKS, or other forms of radiation therapy.
Overall Survival
At last followup, 5 patients (12.5%) were alive and 35 patients (87.5%) had died. The overall median survival time was 6.7 months after first SRS. The Kaplan-Meier survival curve of all 40 of the patients evaluated is docu mented in Fig. 1 . The 6month rate of overall survival was 55% (18 patients had died), and the 1year survival rate was 25% (30 patients had died). Two patients (5%) were alive > 24 months after SRS.
The actuarial 6month and 1year survival rates of 19 patients who underwent radiation therapy (WBRT and/ or local radiation therapy) before SRS were 58 and 21%, respectively, with a median survival period of 6.9 months, and those of 21 patients with no prior radiation therapy were 52 and 29%, respectively, with a median survival period of 6.6 months. The difference between these me dian survival rates was not statistically significant (p = 0.931) (Fig. 2) .
The median survival time for 21 patients with KPS scores ≥ 80 was significantly greater than in the 19 pa tients with KPS scores ≤ 70 (9.4 vs 4.1 months; p = 0.018). The median survival time for the 19 patients with prior radiation therapy was 6.9 months, and that for the 21 patients with no prior radiation therapy was 6.6 months. The difference was not statistically significant (p = 0.931).
The actuarial 6-month survival rate was also significantly greater in patients with KPS scores ≥ 80 than in those with KPS scores ≤ 70 (89 vs 15%; p = 0.002) (Fig. 3) . However, the SIR classification was not found to be a sig nificant prognostic factor for survival in this study (p = 0.811). We could not evaluate the survival rates by using the RPA classification system because of extreme case deviation.
The median survival time of the 24 patients with ex tra cranial sites of metastatic disease was 7.3 months, com pared with a median survival of 5.1 months for the 13 patients with only brain metastases (p = 0.859) (Fig.  4) . The actuarial 6month and 1year survival rates of pa tients with extracranial sites of metastatic disease were 33.3 and 16.7%, respectively, and those of patients with only brain metastases were 30.7 and 23.1%, respectively. These differences were not statistically significant (p = 0.619 and 0.972, respectively).
The analysis of survival period stratified by initial to tal tumor burden (defined as the volume of all intracranial metastatic tumors identified at the first GKS treatment study) ≤ 10 cm 3 (20 patients), and > 10 cm 3 (20 patients) revealed an identical median survival of 6.7 months (p = 0.884).
Multivariate regression analysis (the Cox proportion al hazards model) was performed using several proposed prognostic factors (age, radiation therapy before SRS, KPS score, extracranial metastases, and initial total tu mor burden; Table 3 ). The results identified KPS score as the only statistically significant factor associated with improved survival.
Posttreatment Complications
Five patients (1 with esophageal, 3 with colon, and 1 with rectal cancer) died due to their systemic condition within 1 month after SRS (2-27 days). No patient suf fered from acute neurological complications caused by intratumoral hemorrhage after SRS. In 7 patients (17.5%), transient peritumoral edema was observed after SRS treatments, but steroid therapy was effective in all cases of radiosurgeryinduced edemas.
Discussion
Metastatic brain tumors represent ~ 12% of total brain tumors. The most frequent primary tumor is lung cancer (50%), followed by breast cancer (12%). 38 Colorec tal cancer rarely metastasizes to the brain, and is found in only 2-3% of autopsy cases and 1-4% of clinically di agnosed cases. Brain metastases from esophageal cancer are also unusual, with a reported incidence of between 0.4 and 5.1%. 47 Although pancreatic cancer develops in ~ 27,000 Americans (2% of all cancer diagnoses) each year, 32, 49 nervous system metastasis is rare (0.57%). 31 However, once digestive system cancers metastasize to the lung, the risk of subsequent metastasis to the brain is high. The mechanism of brain metastasis is not well understood, but the affinity between cancerous cells and neuronal tissues may be involved in the process. 46 Several studies reported that 3-8% of all brain metastases are caused by gastrointestinal tract cancers.
12,14,36
Role of SRS for Brain Metastases
Several treatment options exist for symptomatic brain metastases, including WBRT, stereotactic radiation, and surgical intervention, and can be used alone or in com bination. Traditionally, WBRT has been the mainstay of treatment and provides symptomatic improvement in ~ 75% of patients with brain metastases (Fig. 5) . 8, 18 How ever, local treatment failure is ~ 30-40%, and patients may eventually die of their central nervous system dis ease. 28, 34, 35 Overall, WBRT has been reported to provide a poor 1year local tumor control rate of only 0-14%. 20, 34, 35 Although this study was not designed to test the efficacy of WBRT and local radiation therapy directly, reported results in the literature suggest a limited role for these treatments in the control of gastrointestinal carcinomas that metastasize to the brain.
In contrast, SRS for brain metastases results in a high local control rate. 1, 2, 19, 22 Gamma Knife surgery is tradi tionally indicated for brain metastases when the patient's performance status is favorable and tumors are < 3 cm in diameter. 12, 22 As a treatment strategy for brain metastases, SRS has several advantages in comparison with open sur gery or WBRT. The goals of SRS are localized tumor con trol, improvement of clinical symptoms, and prolongation of survival, and it does these things while affording low morbidity and mortality rates. The role of SRS has been validated in many clinical trials. This therapeutic modal ity provides an acceptable local control ranging from 82 to 90% of patients, and an overall median survival of 7 to 12 months has been reported. 2, 12, 23, 43 Overall Survival
In this study, the overall median survival time after GKS in patients with brain metastases from gastrointes tinal system cancers was 6.7 months, compared with the findings in Schoeggl et al. 37 (6 months) and Hasegawa et al. 15 (5 months) (Table 4) . Generally, compared with brain metastases from breast cancer (7.8-13 months), 5, 10, 24 lung cancer (7-15 months) , 30, 39, 41 and renal cell carcinoma (12.5-15 months), 16, 30, 42 the survival of patients with brain metastases from digestive system cancers is shorter. Most patients with gastrointestinal cancers have other extracra nial metastases, especially in the lung and/or in the liver, and their survival is limited by the extracranial disease. In our study, 24 patients (60%) had extracranial metastases, and the incidence of lung, liver, and other systemic tu mors (ovary, omentum, and distant lymph node) was 32.5, 27.5, and 20%, respectively (including duplicated system ic metastatic foci). This compares to Salvati et al., 36 who reported 27% of patients with lung metastases and 12% of patients with liver metastases, and Hasegawa et al., 15 who reported that 44% of patients had extracranial metastases, and that the incidence of lung and liver tumors was 30.8 and 17.9%, respectively.
Statistical Analyses of Survival Time
In univariate testing, a KPS score ≥ 80% was the only factor found to be significant for survival (p = 0.018). Age (< 61 years vs ≥ 61 years), radiation therapy before SRS (WBRT and/or local radiation therapy), extracranial metastases, and total tumor burden were not significant. In multivariate regression analyses, the important factor associated with increased survival was KPS score (p = 0.002). Schoeggl et al. 37 reported that a KPS score of > 70 was a significantly favorable prognostic factor in uni-and multivariate testing.
We investigated the significance of total initial tumor burden in overall survival. In this series, there was no sig nificant difference in the survival rate of patients when comparing those with a total tumor burden of ≤ 10 cm 3 to those with > 10 cm 3 (median survival in both groups was 6.7 months, p = 0.884). For comparison, DiLuna et al. 9 reported that total volume < 5 cm 3 was associated with increased survival, and Nam et al. 26 reported that total volume < 8 cm 3 was significant in their univariate analysis. Amendola et al. 3 reported that total volume < 30 cm 3 was significant in their multivariate analysis; how ever, this cutoff volume is much larger compared with the previously mentioned reports. 9, 26 Finally, Bhatnagar et al. 6 reported that those who had a smaller total tumor volume survived longer, and total treated tumor volume was the only statistically significant factor associated with local recurrence. Thus, there is no standard conclusion about the maximal total brain metastatic volume that affects survival. In our series, the statistical power of the study may not be large enough to detect this particular effect, so we continue to believe that total tumor burden may be an important factor in survival for patients with brain metastases from gastrointestinal carcinomas.
Local Tumor Control
Schoeggl et al. 37 reported that local control of brain metastases from colorectal cancers was achieved in 96% of treated tumors. Hasegawa et al. 15 reported that they achieved an 84% rate of local control of brain metastases from digestive system cancers at the patients' last imag ing study. Local tumor control in our series was achieved in 91%. These results show control rates comparable to those of lung (72.7-94%), 17, 30, 41 breast (90-94%), 10, 21, 24 or renal cell cancers (82.6-96%). 23, 42, 44 In the statistical analyses, there was no statistical significance in the ad ministration of radiation therapy before SRS (p = 0.931). These results suggest that SRS alone may be effective in achieving local control in brain metastases from gastro intestinal cancers.
Brain Metastatic Characteristics of Several Digestive Cancers
There are various kinds of digestive cancers, and each of them has different characteristics. Metastatic dis semination to the brain may be a function of the unique characteristics of different histological types. We re viewed the brain metastatic characteristics and survival times of several digestive cancers.
Colorectal Cancer. Hammoud et al. 14 reported that brain metastases from colorectal cancer with concomi tant liver and/or lung metastases were seen more fre quently than brain metastases alone. They reported that the median survival time after the diagnosis of brain me tastasis was 1 month for patients who received only ste roids, 3 months for those who received radiotherapy, and 9 months for those who underwent surgery. Patanaphan and Salazar 33 reported that the median survival time af ter the diagnosis of brain metastasis was 5.5 months. The median time for development of brain metastases (the metastasisfree interval) was 33 months.
Pancreatic Cancer. Park et al. 31 reported that the me dian survival was 2.9 months in the patients with cerebral metastases and 4.1 months in patients with spinal metas tases. However, intracranial metastases from pancreatic cancer are rare. As of this writing, there are no literature reports about detailed results of radiosurgical treatment of brain metastasis from pancreatic cancer.
Esophageal Cancer. Approximately 2% of patients with esophageal carcinoma had a diagnosis of brain me tastasis. 47 Brain metastases from esophageal carcinoma tended to occur in patients with large primary tumors and/ or disease in advanced clinical stages. The prognosis for these patients is significantly worse than for those without brain metastases, although selected patients may survive longer with intensive brain tumor treatment. 29 Weinberg et al. 47 reported that the median survival for their entire cohort after diagnosis of the primary tumor was 12.6 months, and the median survival after the diagnosis of brain metastasis was 3.8 months. In the group with pre treatment KPS scores of ≥ 70, the median survival after brain metastasis was 26.2 months. 47 Gastric Cancer. Brain metastasis from gastric cancer is rare. At the University of Texas M.D. Anderson Cancer Center, < 1% of patients with primary gastric carcinoma were found to have brain metastases, and York et al. 50 also reported that the median survival time for these patients was 2.4 months (range 5 days-19.2 months) after diag nosis.
Conclusions
Brain metastases from digestive system cancers are extremely rare. Although less frequent, their number is increasing because patients tend to live longer due to earlier diagnosis and more effective intracranial and ex tracranial treatments. In this series, the median survival period of patients with brain metastases from digestive cancers was 6.7 months after GKS, and the local tumor control rate was 91%. The use of GKS provided a high local tumor control rate for these tumors. The KPS score (≤ 70 vs ≥ 80) was found to be the most important factor in survival. Results in this series suggest that GKS can be an effective tool for the control of brain metastases from digestive system cancers.
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